Recent weeks have produced no shortage of headlines about tensions between Rome and Washington. Public exchanges between political leaders have reinforced the impression of a relationship under strain. This time, the skirmishes seem not to be merely tactical: an important trade mission to Miami by Foreign Minister Tajani was canceled because of inflammatory posts by President Trump. However, it is also important to recognize that, beyond temporary frictions, Italy and the US are two growingly intertwined systems.
The spine of the Italy–US partnership increasingly rests on cooperation in high-value sectors such as pharmaceuticals, advanced manufacturing, artificial intelligence and scientific research, extending well beyond the traditional image of American consumers’ appetite for Italian food, fashion and luxury goods.
This evolution is also changing the nature of transatlantic cooperation. The United States is no longer simply a destination for Italian exports. Its innovation ecosystem allows universities, startups, venture capital, large corporations, and governments to operate within the same strategic framework. Italian organizations can embed themselves in the networks where future technologies, industrial standards, and strategic capabilities are being developed.
Pharmaceuticals offer perhaps the clearest example. The United States remains Italy’s largest non-European pharmaceutical market, and the relationship increasingly revolves around research, manufacturing and industrial partnerships rather than simply exports. Behind globally recognized pharmaceutical brands, Italy has developed one of Europe’s most sophisticated ecosystems of contract development and manufacturing organizations (CDMOs), advanced biologics facilities and high-tech laboratories capable of supporting the entire product lifecycle, from clinical development to commercial production. For American giants in pharma and biotech, these assets are valued not simply as production sites, but as strategic partners combining scientific expertise, regulatory credibility and manufacturing flexibility.
For Italian innovators, the United States ecosystem remains attractive because it combines a large market, abundant capital, fewer institutional guardrails, and a persistent willingness to remain at the frontier of scientific discovery. Venture capital is available at a scale unmatched anywhere else, regulatory frameworks often allow faster experimentation, and both public and private investors are prepared to finance technologies whose commercial payoff may still be years away. Increasingly, this momentum is also driven by competition with China. Washington has come to view leadership in artificial intelligence, biotechnology, semiconductors, quantum technologies, and advanced manufacturing as a matter of national security and political influence. Innovation has become both a commercial race and a strategic competition, reinforcing the incentives to invest, experiment, and scale.
Universities occupy an equally important place in this transformation. Academic cooperation between Italy and the United States has traditionally focused on exchanges, joint publications and scientific research. Today, however, those relationships extend beyond the laboratory. University incubators, technology transfer offices and corporate spin-offs are becoming channels through which research moves directly into industrial applications. Many of tomorrow’s strategic technologies will emerge from research teams capable of transforming scientific breakthroughs into scalable businesses.
One aspect of this ecosystem deserves particular attention because it remains relatively unfamiliar in Italy. Across the United States, geopolitical analysis and intelligence are no longer confined to government institutions. They have become an integral component of private innovation. Universities now host centers dedicated to economic security, critical technologies and strategic competition. Venture capital funds employ geopolitical specialists alongside financial analysts. Corporate laboratories and technology companies routinely integrate expertise on export controls, investment screening, supply chain resilience and geopolitical risk into their business decisions.
US business leaders are growing more aware of the pervasiveness of geopolitical risk. As technological leadership becomes inseparable from national security, companies increasingly evaluate research partnerships, acquisitions, and investment decisions through a strategic lens.
Italy has begun moving in this direction, but the mindset remains less widespread. Geopolitical expertise is still often viewed as a reactive function, something to consult during a crisis or before entering a difficult market. Conversely, in the American ecosystem, strategic analysis informs decisions earlier, from research priorities and venture funding to supply chain design and international partnerships. American universities train professionals able to bridge technology, business and geopolitics. Programs in national security, intelligence, technology policy and economic security have expanded rapidly over the past decade. In Italy, on the other hand, geopolitics and intelligence largely remain public-sector disciplines, while companies often seek these capabilities only after the damage is done. As strategic competition reshapes global markets, this educational gap risks becoming an industrial one.
The implications extend well beyond large corporations. Consider an Italian CDMO handling proprietary biological formulas for an American biotech partner. To maintain its position, that firm can no longer focus solely on labor costs or logistics. It must now actively align with its US clients on complex data governance protocols, invest heavily in secure tech infrastructure to meet strict regulatory screening, and fortify its supply chains against unexpected disruptions. Because it sits at the intersection of transatlantic innovation, its operational survival depends in large part on its ability to navigate the evolving landscape of US-China tech competition.
For Italian businesses, this represents an opportunity as much as a challenge. Italy possesses world-class capabilities in advanced manufacturing, engineering, life sciences and applied research. What it has historically lacked is the systematic integration of these strengths with strategic analysis and long-term geopolitical planning. Building closer links with American innovation ecosystems offers an opportunity not simply to access capital or technology, but to absorb a culture that prizes speed, experimentation and collaboration across academia, finance and industry.
For investors, this distinction is significant. Political disagreements may influence headlines and create short-term uncertainty, but ecosystems evolve over decades. Companies embedded in transatlantic research, technology and innovation networks are likely to prove more resilient than those relying solely on traditional export relationships.
The United States will undoubtedly remain a major export market for Italy. The trade relationship will, however, mature if Italy can position itself inside the ecosystems where the next generation of strategic technologies is being conceived, financed and commercialized. That is where the real transatlantic opportunity lies.
